Maxim Group initiated coverage on Zivo Bioscience with a new price target
$ZIVO
Biotechnology: Pharmaceutical Preparations
Health Care
Maxim Group initiated coverage of Zivo Bioscience with a rating of Buy and set a new price target of $9.00
Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/15/2021 | $9.00 | Buy | Maxim Group |
4 - Zivo Bioscience, Inc. (0001101026) (Issuer)
4 - Zivo Bioscience, Inc. (0001101026) (Issuer)
4 - Zivo Bioscience, Inc. (0001101026) (Issuer)
4 - Zivo Bioscience, Inc. (0001101026) (Issuer)
4 - Zivo Bioscience, Inc. (0001101026) (Issuer)
4 - Zivo Bioscience, Inc. (0001101026) (Issuer)
ZIVO Bioscience, Inc. (OTCQB:ZIVO), a biotech and agtech R&D company engaged in the development of therapeutic and nutritional products derived from proprietary algal cultures, announces it has entered into a relationship with one of the world's leading animal health companies to advance ZIVO's novel immune-boosting compounds for use in multiple poultry market segments. The collaboration is expected to expand over time to address significant unmet needs in other livestock and companion animal species. Initially, ZIVO and its partner have executed two agreements that will govern independent studies designed to validate and expand the use of ZIVO's proprietary actives as immune-enhancing bi
ZIVO Bioscience, Inc. (OTCQB:ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced positive results from its second collaborative study with the University of Delaware evaluating the efficacy of several formulations of ZIVO's proprietary active ingredients in mitigating the spread of Low Pathogenicity Avian Influenza (LPAI) virus among poultry. Building upon the outcomes of the initial study, this second study aimed to assess and compare the performance of three different ZIVO formulations in both directly challenged and contact-exposed birds. The study affirm
ZIVO Bioscience, Inc. (OTCQB:ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces plans for a second collaborative study with the University of Delaware. This new study aims to further explore the potential applications of ZIVO's proprietary active ingredients in mitigating the spread of Low Pathogenicity Avian Influenza (LPAI) virus among poultry. ZIVO's previous study with the University of Delaware demonstrated a significant reduction in viral shedding and a delay in disease transmission among treated birds. This new study is designed to further optimize formul
8-K - Zivo Bioscience, Inc. (0001101026) (Filer)
10-Q - Zivo Bioscience, Inc. (0001101026) (Filer)
DEF 14A - Zivo Bioscience, Inc. (0001101026) (Filer)
Maxim Group initiated coverage of Zivo Bioscience with a rating of Buy and set a new price target of $9.00
ZIVOLife to be Granted Exclusive Worldwide Limited License to ZIVO Bioscience Intellectual Property for the Production and Supply of Whole Biomass Algal Products Conference call to be held in early November Zivo Bioscience, Inc. (NASDAQ:ZIVO) (the "Company"), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced plans to create ZIVOLife LLC ("ZIVOLife"), a newly formed wholly-owned subsidiary, to streamline the Company's corporate structure, better capitalize on the global agtech market opportunity and accelerate progress toward generating revenue from the Company's prop
SC 13D/A - Zivo Bioscience, Inc. (0001101026) (Subject)
SC 13D - Zivo Bioscience, Inc. (0001101026) (Subject)
SC 13D - Zivo Bioscience, Inc. (0001101026) (Subject)